Biotage expands licence agreement with 454 Corporation
Biotage expands licence agreement with 454 Corporation Contact: Jeff Bork, President and CEO Tel: +46 734 22 16 60 Uppsala 17 September 2004 Biotage and 454 Corporation have expanded the one-year-old license agreement, which gave 454 Corporation exclusive rights to use sequencing by synthesis and pyrophosphate based sequencing for whole genome and other high density and high throughput applications. The expanded license gives 454 Corporation the exclusive rights to use the technology for all applications on platforms performing over 1536 reactions. Consequently, the minimum royalty of 1